| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 10/14/2004 | US20040204451 Prevention reproduction of virus |
| 10/14/2004 | US20040204438 such as N-[4-(4-amino-1H-imidazol[4,5-c]quinolin-1-yl)butyl]-5-(dimethylamino)-naphthalenesulfonamide; for induction of biosynthesis of cytokines; immunomodulators; antineoplastic agents |
| 10/14/2004 | US20040204437 Substituted arylamine derivatives and methods of use |
| 10/14/2004 | US20040204436 Imidazonaphthyridines |
| 10/14/2004 | US20040204420 Compounds for modulating RNA interference |
| 10/14/2004 | US20040204408 Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity |
| 10/14/2004 | US20040204399 Aerosolized decongestants for the treatment of sinusitis |
| 10/14/2004 | US20040204378 polyazaalkane, polyaminoalkane, or mixed poly(aza/amino)alkane, any carbon atom of which may be hydroxyl, amino, or oxo substituted, and wherein said inhibitor contains at least two nitrogen atoms that are bonded to a lipophilic group; for treating infections in plants or animals |
| 10/14/2004 | US20040204368 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient |
| 10/14/2004 | US20040204355 alpha 7 receptor is the alpha -bungarotoxin sensitive receptor that influences the release of proinflammatory cytokines from macrophages |
| 10/14/2004 | US20040204346 Intermediate for preparing glycopeptide derivatives |
| 10/14/2004 | US20040204345 Using recombinant zinc finger proteins; use in human therapeutic applications such as cancer therapy and altering plant phenotypes, including disease resistance, fruit ripening |
| 10/14/2004 | US20040203118 Polynucleotides and polypeptides of the IFNalpha-14 gene |
| 10/14/2004 | US20040203111 UDP-N-acetylglucosamine: galactose-B1,3-N-acetylgalactosamine-a-R/ (GlcNAc to GalNAc) B1-6 N- acetylglucosaminyltransferase, C2GnT3 |
| 10/14/2004 | US20040203099 Conjugate of a transport protein and a protein for modulation of notch signalling |
| 10/14/2004 | US20040203098 Compounds and methods for modulating activation of NF-kappaB |
| 10/14/2004 | US20040203093 Nucleotide sequence of the haemophilus influenzae rd genome, fragments thereof, and uses thereof |
| 10/14/2004 | US20040203092 UDP-N-acetylglucosamine:galactose-beta1,3-N-acetylgalactosamine-alpha-R/ (GlcNAc to GalNAc) beta1-6 N-acetylglucosaminyltransferase, C2GnT3 |
| 10/14/2004 | US20040203051 Nucleotide sequences coding two or more tumor associated antigens for use in identify modulators of major histocompatibility complex; preventing infections |
| 10/14/2004 | US20040203039 Attenuated salmonella SP12 mutants as antigen carriers |
| 10/14/2004 | US20040203026 preferred cleaving conditions include heating in an acceptable buffer for a time ranging between about 16 and 24 hours at a temperature between about 20 degrees C. and about 37 degrees C |
| 10/14/2004 | US20040202679 truncated papillomavirus L1 protein consisting of an amino acid sequence having one or more carboxy terminal amino acid residues deleted from a full length L1 amino acid sequence, and amino acid residues from a second protein replacing deleted amino acid residues in the truncated L1 protein. |
| 10/14/2004 | US20040202676 using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process |
| 10/14/2004 | US20040202672 Dermatomycosis vaccine |
| 10/14/2004 | US20040202668 combination vaccine kit with one container of acellular pertussis toxoid and FHA, tetanus toxoid, diphtheria toxoid, Hepatitis B surface antigen, and inactivated polio virus, and a second container of conjugates of a carrier protein and a capsular polysaccharide from Streptococcus pneumoniae |
| 10/14/2004 | US20040202647 T cell line specific for a nitrotyrosine-containing compound; antibody specific for a self-antigen comprising a tyrosine to nitrotyrosine conversion; prevention and treatment of autoimmune diseases, infectious diseases and cancer through the recognition of compounds containing nitrated tyrosine residues |
| 10/14/2004 | US20040202643 capable of change from insoluble and stable form to soluble and active form upon a change in temperature, pH, chemical composition, concentration, and/or change in shear force acting upon the crystal; capable of releasing their protein activity at a controlled rate |
| 10/14/2004 | US20040202641 Recombinant super-compound interferon |
| 10/14/2004 | US20040202617 Delivery of opioids through an inhalation route |
| 10/14/2004 | DE10313636A1 Verwendung von Wirksubstanzen zur Vorbeuge oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen The use of active substances for the prevention or treatment of viral diseases and Test System for Finding such active substances |
| 10/14/2004 | CA2734606A1 Polypeptide comprising cell adhesion motif, t cell epitope and b cell epitope for inducing antibody production |
| 10/14/2004 | CA2561840A1 Use of pediocin a for the amelioration of digestive functionality |
| 10/14/2004 | CA2521260A1 Compositions comprising macrolide t-cell immunomodulators or immunosuppressants in combination with antibacterials |
| 10/14/2004 | CA2521056A1 Hydrazone derivative |
| 10/14/2004 | CA2521055A1 Methyl-.beta.-orcinolcarboxylate from lichen (everniastrum cirrhatum) for use for the treatment of fungal infections and cancer |
| 10/14/2004 | CA2520896A1 Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase |
| 10/14/2004 | CA2520764A1 4-substituted quinolein derivatives with antimicrobial activity |
| 10/14/2004 | CA2520723A1 N-aryl-2-oxazolidinone-5-carboxamides derivatives with antibacterial activity |
| 10/14/2004 | CA2520682A1 Crystalline n-formyl hydroxylamine compounds |
| 10/14/2004 | CA2520400A1 Treatment of aspergillus infections with thymosin alpha 1 |
| 10/14/2004 | CA2520389A1 Method and compositions for conversion of antibody activity |
| 10/13/2004 | EP1466924A1 Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV |
| 10/13/2004 | EP1466904A1 Biaryl compound and use thereof |
| 10/13/2004 | EP1466624A1 Drug for regenerating tissue and vessel and method therefor |
| 10/13/2004 | EP1466619A2 Method for modulating cell apoptosis |
| 10/13/2004 | EP1466615A1 Pharmaceutical composition |
| 10/13/2004 | EP1466611A1 Use of HCG derived peptides in the treatment of iatrogenic diseases |
| 10/13/2004 | EP1466603A2 Novel catechols as antimicrobial agents |
| 10/13/2004 | EP1465997A2 Use of biomolecular targets in the treatment and visualization of tumors |
| 10/13/2004 | EP1465990A2 Truncated lysostaphin molecule with enhanced staphylolytic activity |
| 10/13/2004 | EP1465928A2 Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies |
| 10/13/2004 | EP1465926A2 Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies |
| 10/13/2004 | EP1465924A2 Modulators of notch ic protease activity for use in immunotherapy |
| 10/13/2004 | EP1465914A1 Triterpene quaternary salts as biologically active surfactants |
| 10/13/2004 | EP1465908A2 Compositions and methods for hydroxylating epothilones |
| 10/13/2004 | EP1465898A1 Biocidal compounds and their preparation |
| 10/13/2004 | EP1465895A2 4-oxo-4,7-dihydrofuro(2,3-b)pyridine-5-carboxamide antiviral agents |
| 10/13/2004 | EP1465894A2 Synthesis and purification of valacyclovir |
| 10/13/2004 | EP1465891A2 Inhibitors of dipeptidyl peptidase iv |
| 10/13/2004 | EP1465889A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| 10/13/2004 | EP1465659A2 Use of a novel cell surface protease from group b streptococcus |
| 10/13/2004 | EP1465642A1 Protection against the neurotoxicity of oxaliplatin through the administration of calcium and magnesium |
| 10/13/2004 | EP1465640A1 Use of polysaccharide derivatives as anti-infective substances |
| 10/13/2004 | EP1465634A2 Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation |
| 10/13/2004 | EP1465625A2 Solubilized topoisomerase poisons |
| 10/13/2004 | EP1465596A1 Polymeric gel system for the controlled delivery of codrugs |
| 10/13/2004 | EP1465591A1 Antibiotic product, use and formulation thereof |
| 10/13/2004 | EP1465491A1 Antiseptic compositions and methods |
| 10/13/2004 | EP1465488A1 Arylamines as inhibitors of chemokine binding to us28 |
| 10/13/2004 | EP1397137A4 Hydantion derivatives as inhibitors of matrix metalloproteinases |
| 10/13/2004 | EP1322309A4 High affinity small molecule c5a receptor modulators |
| 10/13/2004 | EP1313500B1 Combinations of dalfopristine/quinupristine with cefpirome |
| 10/13/2004 | EP1280820B1 Anti-inflammatory compounds and uses thereof |
| 10/13/2004 | EP1277750B1 Hydrates and crystals of a neuraminic acid compound |
| 10/13/2004 | EP1251133B1 Novel carbapenem derivatives |
| 10/13/2004 | EP1248603B1 Use of particular compounds for prophylaxis and treatment of hepatitis c |
| 10/13/2004 | EP1202965B1 Indole derivatives, processes for their preparation, pharmaceutical compositions containing them and their medicinal application |
| 10/13/2004 | EP1177217B1 Amphiphile cyclodextrins, preparation and use thereof for solubilising organised systems and incorporating hydrophobic molecules |
| 10/13/2004 | EP1152765B1 Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof |
| 10/13/2004 | EP1144428B1 Method for preparing an aza-macrolide with 4"(r)-nh2 |
| 10/13/2004 | EP1131340B1 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 10/13/2004 | EP1128831B1 Pharmaceutical moxifloxacin preparation |
| 10/13/2004 | EP1093366B1 Pharmaceutical composition containing gaba analogs and an antiviral agent to treat shingles |
| 10/13/2004 | EP1086086B1 Imidazolyl derivatives and their use as somatostatin receptor ligands |
| 10/13/2004 | EP1079790B1 Use of microbicidal and spermicidal compositions for inactivating non-enveloped viruses |
| 10/13/2004 | EP1077956B1 3-substituted 5-aryl-4-isoxazolecarbonitriles having antiviral activity |
| 10/13/2004 | EP1003762B1 Base analogues |
| 10/13/2004 | EP0848712B1 Dihydropyran derivatives as viral neuraminidase inhibitors |
| 10/13/2004 | CN1537162A Attenuated circovirus |
| 10/13/2004 | CN1537112A Pyrimidine compound |
| 10/13/2004 | CN1537111A Urea substituted imidazoquinolines |
| 10/13/2004 | CN1537019A Medical combination of aldosterone receptor antagonist and HMG CoA reductase inhibitor |
| 10/13/2004 | CN1537015A Stable liquid formulations of antibodies |
| 10/13/2004 | CN1537011A Composition for prevention and treatment of influenza having antivirus effect |
| 10/13/2004 | CN1537009A Method for treating or preventing functional vitamin B12 dificiency in individual and to medical compositions for use in said method |
| 10/13/2004 | CN1537005A Amorphous cefditoren pivoxil composition and process for producing the same |
| 10/13/2004 | CN1537003A Pharmaceutical composition comprising tricyclic compound for prevention or treatment of skin diseases |
| 10/13/2004 | CN1537000A Novel imidazolidine derivatives, their preparation and their use as VLA-4 antagonists |
| 10/13/2004 | CN1536986A Intravaginal drug delivery devices for administration of antimicrobial agent |
| 10/13/2004 | CN1536967A Nutritional composition preventing bacterial overgrowth |